Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 13;492(7428):252-5.
doi: 10.1038/nature11603. Epub 2012 Nov 11.

Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability

Weiquan Zhu  1 , Nyall R London, Christopher C Gibson, Chadwick T Davis, Zongzhong Tong, Lise K Sorensen, Dallas S Shi, Jinping Guo, Matthew C P Smith, Allie H Grossmann, Kirk R Thomas, Dean Y Li
Affiliations

Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability

Weiquan Zhu et al. Nature. .

Abstract

The innate immune response is essential for combating infectious disease. Macrophages and other cells respond to infection by releasing cytokines, such as interleukin-1β (IL-1β), which in turn activate a well-described, myeloid-differentiation factor 88 (MYD88)-mediated, nuclear factor-κB (NF-κB)-dependent transcriptional pathway that results in inflammatory-cell activation and recruitment. Endothelial cells, which usually serve as a barrier to the movement of inflammatory cells out of the blood and into tissue, are also critical mediators of the inflammatory response. Paradoxically, the cytokines vital to a successful immune defence also have disruptive effects on endothelial cell-cell interactions and can trigger degradation of barrier function and dissociation of tissue architecture. The mechanism of this barrier dissolution and its relationship to the canonical NF-κB pathway remain poorly defined. Here we show that the direct, immediate and disruptive effects of IL-1β on endothelial stability in a human in vitro cell model are NF-κB independent and are instead the result of signalling through the small GTPase ADP-ribosylation factor 6 (ARF6) and its activator ARF nucleotide binding site opener (ARNO; also known as CYTH2). Moreover, we show that ARNO binds directly to the adaptor protein MYD88, and thus propose MYD88-ARNO-ARF6 as a proximal IL-1β signalling pathway distinct from that mediated by NF-κB. Finally, we show that SecinH3, an inhibitor of ARF guanine nucleotide-exchange factors such as ARNO, enhances vascular stability and significantly improves outcomes in animal models of inflammatory arthritis and acute inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Immediate effects of IL-1β are NF-κB independent and ARF6 dependent
Monolayers of HMVEC-D stimulated with IL-1β assayed for: (a) permeability to horse-radish peroxidase (HRP) over time; (b) permeability to HRP following two hours treatment with SC514; (c) immunofluorescent localization of VE-cadherin; (d) permeability to HRP after thirty minutes treatment with Actinomycin-D, or Cycloheximide. (e) IL-1β-stimulated HMVEC-D lysates precipitated with GST-GGA3 and immunoblotted for ARF6. HMVEC-D monolayers infected with Ad-GFP or Ad-ARF6-Q67L: (f) permeability; (g) VE-cadherin (red) localization, ARF6 expression (green). Membrane fractions from (h) adenoviral-vector infected or (i) ARF6 siRNA-treated HMVEC-D immunoblotted for VE-cadherin. ARF6 siRNA-treated HMVEC-D stimulated with IL-1β: (j) VE-cadherin (arrows=disrupted VE-cadherin cell-surface localization) (k) permeability. N≥3; error bars=SEM. *p<0.05, **p<0.01, ***p<0.001.
Figure 2
Figure 2. Inhibition of ARF-GAPs and ARF-GEFs affect ARF6 activation and VE-cadherin localization
HMVEC-D treated with QS11: (a) whole-cell lysates precipitated with GST-GGA3 and immunoblotted for ARF6; b) membrane fractions immunoblotted for VE-cadherin. (c) immunofluorescence for VE-cadherin (red); (d) permeability to HRP. HMVEC-D treated with IL-1β and SecinH3: (e) immunoblotting for ARF6; (f) Immunofluorescence for VE-cadherin (red); (g) permeability to HRP. HMVEC-D treated with anti-ARNO siRNA and stimulated with IL-1β: (h) permeability to HRP; (i) GST-GGA3 precipitation and ARF6 immunoblotting; (j) immunofluorescence of VE-cadherin (red) (Arrow=less cell-surface VE-cadherin. N≥3; error bars=SEM. *p<0.05, **p<0.01, ***p<0.001.
Figure 3
Figure 3. The immediate IL-1β-induced permeability pathway diverges at MYD88
(a) IRAK1 siRNA treated HMVEC-D, stimulated with IL-1β, subjected to GTP-ARF6 pull down and immunoblotted for ARF6. MYD88 siRNA-treated HMVEC-D stimulated with IL-1β: (b) permeability; (c) ARF6 activation. (d) NF-κB p65 immunofluorescence of HMVEC-D stimulated with IL-1β and SecinH3. (Arrow=nuclear localization). (e) Cell lysates from Ad ARNO-Myc infected HMVEC-D immunoprecipitated with anti-Myc antibodies and immunoblotted with anti-MYD88 antibodies. (f) Lysates from HMVEC-D immunoprecipitated with anti-MYD88 antibodies and immunoblotted with anti-ARNO antibodies. N≥3, error bars=SEM, * p<0.05, ** p<0.01, *** p<0.001.
Figure 4
Figure 4. Inhibition of ARF-GEFs decreases CIA-induced vascular permeability and arthritis
(a) Arthritis-induced vascular permeability in the joint measured by Evans Blue leak seven days after treatment initiation in the presence of SecinH3 or Enbrel. N=14 per group. (b) Chronological arthritic assessment. N=10/group. (c) H&E staining of sections through joints; Bn=bone, HC=hyaline cartilage, JS=joint space, Pn=inflammed pannus, *cartilage & bone loss, arrows=eroded cartilage. (d) Summary of histological changes of inflammation, pannus, cartilage, and bone damage of indicated treatment. Control, N=5; Enbrel and SecinH3, N=10; error bars=SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs disease group.
See this image and copyright information in PMC

Comment in

  • A new path to treating arthritis?
    Onuora S. Onuora S. Nat Rev Rheumatol. 2013 Jan;9(1):2. doi: 10.1038/nrrheum.2012.209. Epub 2012 Nov 27. Nat Rev Rheumatol. 2013. PMID: 23183926 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nature reviews. Immunology. 2:725–734. - PubMed
    1. Collins T, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995;9:899–909. - PubMed
    1. Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. 2006;290:L622–L645. - PubMed
    1. RothwARF DM, Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE. 1999:RE1. - PubMed
    1. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nature reviews Immunology. 2007;7:803–815. - PubMed

Publication types

MeSH terms